New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
August 16, 2017 – The FDA approved a new warning to the Tysabri (natalizumab) drug label regarding acute retinal necrosis (ARN).
Download PDF
Return to publications
